Bolt Biotherapeutics Financial Performance for the Quarter
Thursday, 21 March 2024, 20:54
Bolt Biotherapeutics Financial Performance
Bolt Biotherapeutics reported a GAAP EPS of -$0.47, which was in line with expectations. The company's revenue of $2.1M exceeded analysts' estimates by $0.31M.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.